Kinoxis Therapeutics
Melbourne, AU Β· Founded 2017 Β· 2 known investors
Kinoxis Therapeutics develops small-molecule drugs for disorders of the brain and mind, including its lead candidate KNX100 for agitation associated with dementia, substance use disorders (such as alcohol and opioid withdrawal), and chronic pain. The clinical-stage biotech is based in Australia and advances its therapies through clinical studies including the Phase 2a CARES-X trial.
BiotechHealthtech
Investors Β· 2
Frequently asked questions
- What does Kinoxis Therapeutics do?
- Kinoxis Therapeutics develops small-molecule drugs for disorders of the brain and mind, including its lead candidate KNX100 for agitation associated with dementia, substance use disorders (such as alcohol and opioid withdrawal), and chronic pain. The clinical-stage biotech is based in Australia and advances its therapies through clinical studies including the Phase 2a CARES-X trial.
- Who are Kinoxis Therapeutics's investors?
- Kinoxis Therapeutics's investors include Stoic VC, UniSeed Pty Ltd..
- Where is Kinoxis Therapeutics headquartered?
- Kinoxis Therapeutics is headquartered in Melbourne, AU.